Stocks Overview

LAST PRICE
233.6000
TODAY'S CHANGE (%)
Trending Up2.6200 (1.1343%)

Bid / Lots
225.5100/ 1
Ask / Lots
236.6000/ 2
Open / Previous Close
236.2400 / 230.9800
Day Range
Low 227.4300
High 238.8000
52 Week Range
Low 126.9681
High 238.8000
Volume
410,278
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Tuesday's close: 230.98
Time	Volume	BGNE
09:32 ET	8813	237.67
09:34 ET	1207	238.49
09:36 ET	2405	237.34
09:38 ET	2117	237.06
09:39 ET	1707	236.99
09:41 ET	750	236.5
09:43 ET	1286	235.61
09:45 ET	300	236.08
09:48 ET	6997	234.355
09:50 ET	4333	233.42
09:52 ET	600	234.35
09:54 ET	2376	233.34
09:56 ET	13750	232.73
09:57 ET	5350	231.42
09:59 ET	1252	231
10:01 ET	1200	230.08
10:03 ET	800	229.22
10:06 ET	300	230.14
10:08 ET	1310	229.96
10:10 ET	5197	228.875
10:12 ET	2850	229
10:14 ET	1166	229.15
10:15 ET	1200	228.78
10:17 ET	1202	228.25
10:19 ET	1510	227.96
10:21 ET	1000	228.3
10:24 ET	2100	227.6
10:26 ET	4308	227.8875
10:28 ET	239	227.8875
10:30 ET	921	228.49
10:32 ET	12112	227.96
10:33 ET	573	227.76
10:35 ET	600	228.66
10:37 ET	500	228.7
10:39 ET	1273	229.15
10:42 ET	200	228.995
10:44 ET	800	229.5
10:46 ET	1608	229.67
10:48 ET	1662	229.13
10:50 ET	300	229.44
10:51 ET	2823	230.3105
10:53 ET	300	230.515
10:55 ET	151	230.175
10:57 ET	550	229.2
11:00 ET	500	229.075
11:02 ET	325	228.825
11:04 ET	400	229
11:06 ET	900	228.87
11:08 ET	1680	228.57
11:09 ET	500	228.41
11:11 ET	2300	228.3
11:13 ET	102	228.3
11:15 ET	100	228.295
11:20 ET	100	228.2675
11:22 ET	2029	229.5
11:24 ET	262	229.275
11:26 ET	183	229.23
11:27 ET	534	228.855
11:29 ET	113	228.955
11:33 ET	1300	228.94
11:36 ET	1048	229.04
11:38 ET	571	229.115
11:40 ET	2619	228.785
11:42 ET	1637	228.75
11:45 ET	400	228.675
11:47 ET	100	228.67
11:49 ET	306	228.655
11:51 ET	108	228.64
11:54 ET	943	228.62
11:56 ET	200	228.61
11:58 ET	2711	229.3
12:00 ET	200	229.42
12:02 ET	400	229.415
12:03 ET	210	229.63
12:05 ET	634	229.61
12:07 ET	400	229.65
12:12 ET	502	229.79
12:14 ET	200	229.63
12:16 ET	1108	230.095
12:18 ET	200	229.9759
12:20 ET	207	230.18
12:21 ET	1679	229.9485
12:23 ET	117	229.73
12:25 ET	777	230.195
12:27 ET	200	230.285
12:30 ET	1306	230.09
12:32 ET	1085	229.72
12:36 ET	453	229.325
12:38 ET	1000	229.28
12:43 ET	449	229.18
12:45 ET	200	228.99
12:48 ET	333	228.98
12:50 ET	1767	229.54
12:52 ET	100	229.57
12:54 ET	210	229.79
12:56 ET	522	229.19
12:57 ET	334	229.02
01:01 ET	845	229.44
01:03 ET	100	229.37
01:06 ET	212	229.29
01:08 ET	479	229.285
01:12 ET	4103	229.915
01:14 ET	200	229.895
01:17 ET	2367	230
01:19 ET	100	229.91
01:21 ET	257	229.81
01:24 ET	200	230.19
01:28 ET	800	230.29
01:30 ET	101	230.595
01:32 ET	130	230.99
01:37 ET	1500	230.765
01:39 ET	200	231.2
01:42 ET	1449	231.37
01:44 ET	310	231.345
01:46 ET	200	231.2
01:48 ET	1050	231.37
01:50 ET	110	231.67
01:53 ET	100	231.37
01:55 ET	721	231.15
01:57 ET	800	231.32
02:00 ET	100	231.53
02:02 ET	363	231.57
02:04 ET	5898	231.38
02:06 ET	511	231.085
02:08 ET	250	231.27
02:09 ET	200	231.065
02:13 ET	300	231.36
02:15 ET	1100	231.39
02:18 ET	200	231.52
02:20 ET	649	231.385
02:22 ET	593	231.35
02:27 ET	100	231.36
02:29 ET	1047	231.4
02:31 ET	200	231.67
02:33 ET	300	231.515
02:36 ET	700	231.69
02:38 ET	200	231.7
02:42 ET	341	231.69
02:44 ET	1624	231.38
02:45 ET	200	231.38
02:47 ET	1000	231.355
02:49 ET	300	231.48
02:51 ET	200	231.465
02:54 ET	505	231.5
02:56 ET	327	231.455
02:58 ET	529	231.31
03:00 ET	1093	231.31
03:02 ET	2220	231.6
03:03 ET	607	231.78
03:05 ET	100	231.64
03:07 ET	200	231.95
03:09 ET	175	232.075
03:12 ET	200	232.25
03:14 ET	1268	232.46
03:16 ET	500	232.71
03:18 ET	429	232.87
03:21 ET	219	232.84
03:23 ET	2087	232.82
03:25 ET	336	232.6
03:27 ET	2533	232.91
03:30 ET	300	233.31
03:32 ET	515	233.61
03:34 ET	510	233.52
03:36 ET	617	233.65
03:38 ET	451	233.77
03:41 ET	646	233.475
03:43 ET	8087	233.6
03:45 ET	475	233.49
03:48 ET	648	233.5631
03:50 ET	3883	233.86
03:52 ET	2518	233.9025
03:54 ET	3053	233.405
03:56 ET	2645	233.68
03:57 ET	4672	233.65
03:59 ET	28103	233.6

Data delayed at least 15 minutes.

Sep 26, 2024
- BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA(R), for Treatment of ESCC and Gastric/GEJ Cancers, from 6:21PM ET on Thursday Sep 26, 2024 by Dow Jones
  6:21PM ET on Thursday Sep 26, 2024 by Dow Jones
- Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors, from 6:00AM ET on Thursday Sep 26, 2024 by Dow Jones
  6:00AM ET on Thursday Sep 26, 2024 by Dow Jones
- *DJ BeiGene Appoints Shalini Sharp to Board of Directors, from 6:00AM ET on Thursday Sep 26, 2024 by Dow Jones
  6:00AM ET on Thursday Sep 26, 2024 by Dow Jones
Sep 18, 2024
- DJ BeiGene Initiated at Market Outperform by JMP Securities, from 5:52AM ET on Wednesday Sep 18, 2024 by Dow Jones
  5:52AM ET on Wednesday Sep 18, 2024 by Dow Jones
Sep 17, 2024
- BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA(R) for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy, from 7:00AM ET on Tuesday Sep 17, 2024 by Dow Jones
  7:00AM ET on Tuesday Sep 17, 2024 by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesBGNE Beigene Ltd	26.5B	-46.0x	---
United StatesUTHR United Therapeutics Corp	15.9B	16.2x	+8.22%
United StatesALNY Alnylam Pharmaceuticals Inc	35.4B	-432.1x	---
United StatesBMRN Biomarin Pharmaceutical Inc	13.3B	52.5x	---
United StatesEXAS Exact Sciences Corp	12.6B	-69.6x	---
United StatesARGX argenx SE	32.8B	-158.1x	---
As of 2024-10-02

BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Contact Information

Headquarters: C/O Mourant Governance Services (Cayman) 94 Solaris Avenue, Camana BayGRAND CAYMAN, BEJ, Cayman Islands KY1-1108
Phone: 345-949-4123
Fax: ---

Executives

Co-Founder, Executive Chairman of the Board, Chief Executive Officer: John Oyler
President, Chief Operating Officer, General Manager - China: Xiaobin Wu
Co-Founder, Non-Executive Director: Xiaodong Wang
Chief Financial Officer: Aaron Rosenberg
General Manager, North America: Matthew Shaulis

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$26.5B
Revenue (TTM)	$3.1B
Shares Outstanding	106.1M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	0.61
EPS	$-5.08
Book Value	$36.95
P/E Ratio	-46.0x
Price/Sales (TTM)	8.6
Price/Cash Flow (TTM)	---
Operating Margin	-16.90%

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Beigene Ltd
NASDAQ:BGNEUnited States

Search Criteria

Charts

Recent News

Sep 26, 2024

BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA(R), for Treatment of ESCC and Gastric/GEJ Cancers, from 6:21PM ET on Thursday Sep 26, 2024 by Dow Jones

Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors, from 6:00AM ET on Thursday Sep 26, 2024 by Dow Jones

*DJ BeiGene Appoints Shalini Sharp to Board of Directors, from 6:00AM ET on Thursday Sep 26, 2024 by Dow Jones

Sep 18, 2024

DJ BeiGene Initiated at Market Outperform by JMP Securities, from 5:52AM ET on Wednesday Sep 18, 2024 by Dow Jones

Sep 17, 2024

BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA(R) for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy, from 7:00AM ET on Tuesday Sep 17, 2024 by Dow Jones

Biotechnology Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar